Print Page  Close Window     


SEC Filings


8-K
VANDA PHARMACEUTICALS INC. filed this Form 8-K on 08/01/2018
Entire Document
 << Previous Page | Next Page >>


VANDA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except for share and per share amounts)

(unaudited)

 

     Three Months Ended     Six Months Ended  
     June 30
2018
     June 30
2017
    June 30
2018
     June 30
2017
 

Revenues:

          

HETLIOZ® product sales, net

   $ 28,045      $ 22,507     $ 53,468      $ 42,689  

Fanapt® product sales, net

     19,305        19,549       37,474        36,782  
  

 

 

    

 

 

   

 

 

    

 

 

 

Total revenues

     47,350        42,056       90,942        79,471  

Operating expenses:

          

Cost of goods sold excluding amortization

     5,213        4,529       9,773        8,532  

Research and development

     9,866        7,648       19,282        18,215  

Selling, general and administrative

     27,960        31,371       54,782        61,668  

Intangible asset amortization

     398        432       750        886  
  

 

 

    

 

 

   

 

 

    

 

 

 

Total operating expenses

     43,437        43,980       84,587        89,301  
  

 

 

    

 

 

   

 

 

    

 

 

 

Income (loss) from operations

     3,913        (1,924     6,355        (9,830

Other income

     788        397       1,410        677  
  

 

 

    

 

 

   

 

 

    

 

 

 

Income (loss) before income taxes

     4,701        (1,527     7,765        (9,153

Provision for income taxes

     90        7       88        26  
  

 

 

    

 

 

   

 

 

    

 

 

 

Net income (loss)

   $ 4,611      $ (1,534   $ 7,677      $ (9,179
  

 

 

    

 

 

   

 

 

    

 

 

 

Net income (loss) per share, basic

   $ 0.09      $ (0.03   $ 0.16      $ (0.21

Net income (loss) per share, diluted

   $ 0.09      $ (0.03   $ 0.15      $ (0.21

Weighted average shares outstanding, basic

     52,172,982        44,718,597       49,270,829        44,559,368  

Weighted average shares outstanding, diluted

     53,945,640        44,718,597       51,101,464        44,559,368  

 

Page 5 of 7

 << Previous Page | Next Page >>